Weekly Investment Analysts’ Ratings Changes for Biogen (BIIB)

27 Nov 2025, 18:34 by Amy Steele · The Cerbat Gem

Biogen (NASDAQ: BIIB) recently received a number of ratings updates from brokerages and research firms:

11/25/2025 – Biogen was upgraded by analysts at Weiss Ratings from a “sell (d+)” rating to a “hold (c-)” rating.
11/21/2025 – Biogen had its “neutral” rating reaffirmed by analysts at Piper Sandler. They now have a $157.00 price target on the stock, up previously from $118.00.
11/19/2025 – Biogen had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
11/13/2025 – Biogen had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
11/9/2025 – Biogen was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
11/7/2025 – Biogen was downgraded by analysts at Weiss Ratings from a “hold (c-)” rating to a “sell (d+)” rating.
11/6/2025 – Biogen was upgraded by analysts at Stifel Nicolaus from a “hold” rating to a “buy” rating. They now have a $202.00 price target on the stock, up previously from $144.00.
11/3/2025 – Biogen was given a new $157.00 price target on by analysts at Tudor Pickering.
11/3/2025 – Biogen had its price target raised by analysts at Mizuho from $169.00 to $177.00. They now have an “outperform” rating on the stock.
11/3/2025 – Biogen had its price target raised by analysts at Sanford C. Bernstein from $155.00 to $157.00. They now have a “market perform” rating on the stock.
11/1/2025 – Biogen was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating.
10/31/2025 – Biogen had its price target raised by analysts at Wells Fargo & Company from $140.00 to $155.00.
10/31/2025 – Biogen had its price target raised by analysts at Wedbush from $135.00 to $143.00. They now have a “neutral” rating on the stock.
10/31/2025 – Biogen had its price target raised by analysts at Guggenheim from $165.00 to $185.00.
10/31/2025 – Biogen had its price target raised by analysts at BMO Capital Markets from $128.00 to $150.00.
10/31/2025 – Biogen had its price target lowered by analysts at Royal Bank Of Canada from $217.00 to $210.00. They now have an “outperform” rating on the stock.
10/31/2025 – Biogen had its price target lowered by analysts at Robert W. Baird from $255.00 to $250.00.
10/24/2025 – Biogen was upgraded by analysts at Weiss Ratings from a “sell (d+)” rating to a “hold (c-)” rating.
10/14/2025 – Biogen had its price target raised by analysts at Wedbush from $129.00 to $135.00. They now have a “neutral” rating on the stock.
10/10/2025 – Biogen had its price target raised by analysts at Morgan Stanley from $144.00 to $149.00. They now have an “equal weight” rating on the stock.
10/8/2025 – Biogen had its “sell (d+)” rating reaffirmed by analysts at Weiss Ratings.
10/8/2025 – Biogen had its price target lowered by analysts at Royal Bank Of Canada from $219.00 to $217.00. They now have an “outperform” rating on the stock.
10/6/2025 – Biogen had its price target raised by analysts at Rothschild & Co Redburn from $149.00 to $150.00. They now have a “neutral” rating on the stock.
9/28/2025 – Biogen was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating.

Insider Activity

In related news, insider Priya Singhal sold 517 shares of the stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $133.55, for a total transaction of $69,045.35. Following the transaction, the insider owned 5,772 shares of the company’s stock, valued at approximately $770,850.60. This represents a 8.22% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.18% of the company’s stock.

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.

Weekly Investment Analysts’ Ratings Changes for Biogen (BIIB)

Insider Activity

Featured Stories